Side-by-side comparison of AI visibility scores, market position, and capabilities
Intravascular Lithotripsy & Calcified Artery Treatment Devices
Amplitude Vascular Systems (AVS) is a medical device company developing the Pulse IVL system — a high-frequency pulsatile pressure wave device for treating calcified peripheral artery disease; raised $75M+ total;
Amplitude Vascular Systems (AVS) is a medical device company headquartered in Fremont, California, founded to develop next-generation intravascular lithotripsy (IVL) technology for treating calcified peripheral artery disease (PAD). The company''s flagship product, the Pulse IVL system, delivers high-frequency pulsatile pressure waves through a catheter-based device to fracture calcium deposits in arterial walls — restoring vessel compliance and improving blood flow in patients with calcified, obstructed arteries in the legs, below-the-knee vessels, and other peripheral vascular territories. Calcified PAD is a significant and growing clinical problem, particularly in diabetic patients and the aging population, where conventional balloon angioplasty and stenting are less effective due to hard, calcified lesion morphology.
Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.
Amplitude Vascular Systems vs
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.